Cumberland Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio0.880.680.781.921.18
P/B Ratio1.480.910.911.620.94
Price/Tangible Book8.394.396.833.832.46
Price/FCF4.593.9011.048.40
Price/OCF4.383.8510.868.18
PEG Ratio1.521.521.521.521.52
Enterprise Value Ratios
EV/Revenue0.980.670.731.650.98
EV/FCF4.563.679.496.99
Profitability & Returns
Return on Equity (ROE)-0.25%-0.19%-0.14%-0.13%-0.14%
Return on Assets (ROA)-0.05%-0.04%-0.04%-0.05%-0.04%
Return on Invested Capital (ROIC)-0.24%-0.19%-0.17%-0.22%-0.15%
Return on Capital Employed (ROCE)-0.15%-0.12%-0.09%-0.12%-0.09%
Leverage & Solvency Ratios
Debt/Equity0.910.630.580.380.36
Debt/EBITDA50.3932.1015.97
Debt/FCF3.172.512.573.24
Liquidity Ratios
Current Ratio1.151.281.602.371.95
Quick Ratio0.941.001.151.761.45
Efficiency Ratios
Asset Turnover0.480.450.470.400.37
Inventory Turnover1.530.841.000.920.89
Yield & Distribution Ratios
Earnings Yield-0.19%-0.24%-0.17%-0.05%-0.08%
FCF Yield-0.02%0.22%0.26%0.09%0.12%
Buyback Yield0.02%0.02%0.02%0.02%0.02%